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upper extremity of these elderly patients with very fair skin. The preferred 
treatment was physical destruction of the lesions instead of noninvasive topical 
therapy.  
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OBJECTIVES: Actinic keratoses are common dysplastic epidermal lesions which 
occur in pale-skinned individuals who are chronically exposed to intense 
sunlight. It is one of the most commonly treated skin conditions. The objective of 
this research is to describe the Brazilian profile of solar exposition and the 
sunscreening agents use in patients with AK. METHODS: A two months health 
survey was performed in São Paulo city in which 10 dermatologists registered 
the profile of solar exposition and the sunscreening agents use of a sample of 
patients with AK. RESULTS: Of a total of 4961 patients, 269 (5,4%) patients were 
diagnosed with AK of which 58% were females. The mean age of the patients 
was 65 years old. Before AK diagnosis 91% of the patients exposed themselves to 
the sun mainly for leisure during weekends and only 26% used sunscreening 
agents. After AK diagnosis 43% of the patients still had the habit of solar 
exposition, however 78% uses sunscreening agents. The sun protection factor 
(SPF) most used before of the diagnosis was SPF15 (44%) and SPF30 (38%), 
changing to SPF30 (40%) and SPF60 (33%) after the diagnosis. CONCLUSIONS: 
This data suggest that the São Paulo city population with actinic keratosis 
presents the habit of leisure solar exposition with insufficient use of 
sunscreening agents. The use of sunscreening agents increases after the 
diagnosis of the disease.  
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OBJECTIVES: Overactive bladder (OAB) treatment guidelines recommend 
antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-
class beta-3 adrenoceptor agonist which is licensed for the treatment of OAB and 
has shown to be well tolerated and effective in the treatment of OAB symptoms. 
A systematic literature review and Mixed Treatment Comparisons (MTC) were 
performed to assess the efficacy and tolerability of OAB medications, and more 
specifically mirabegron 50 mg vs. antimuscarinics in patients with OAB. 
METHODS: This review included randomised controlled trials (RCTs) estimating 
changes in symptoms (micturition frequency, incontinence and urgency 
incontinence episodes) and probabilities of the most frequently reported adverse 
events associated with current OAB medications. Literature searches were 
performed on published peer reviewed articles from 2000 to 2012. The following 
drugs were considered in addition to mirabegron: tolterodine immediate release 
(IR) and extended release (ER), oxybutynin IR/ER, trospium, solifenacin, and 
fesoterodine. A Bayesian MTC was performed, with tolterodine ER 4 mg as 
reference comparator. RESULTS: 40 RCTs involving 26,033 patients were 
included. The deviance information criteria was minimised with the random 
effects model for dry mouth and with fixed effect model for other outcomes. The 
mixed treatment comparison showed that mirabegron 50mg had similar efficacy 
to most antimuscarinics in terms of micturition frequency, incontinence 
episodes and urgency urinary incontinence episodes. Mirabegron 50mg also had 
a probability of dry mouth similar to placebo, and significantly lower than all 
included antimuscarinics. CONCLUSIONS: Improvements of OAB symptoms 
were demonstrated for all reviewed OAB treatments versus placebo. Mirabegron 
50mg had similar efficacy to most antimuscarinics, and the lowest incidence of 
dry mouth, which is one of the main causes of discontinuation of 
antimuscarinics.  
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OBJECTIVES: To analyze the cost of treatment alternatives at different stages 
along kidney transplantation. METHODS: A Cost Analysis was developed to 
compare different treatment pathways alternatives for patients with kidney 
transplantation maintenance. Direct and Indirect costs were included. Four 
stages were identified for the cost analysis (induction, initial, maintenance and 
rejection). Each stage has different treatment alternatives, a combination of 
them were compared including medical services and drug costs. The perspective 
of the analysis was institutional. The resource use was identified by expert panel 
of clinicians, and medical literature. Cost valuation uses unitary cost list of the 
Mexican Institute of Social Security (IMSS). Drug costs are those from public 
tenders 2012. Initially, two scenarios were compared; the first was performed 
using the most common treatments available in the Institutions, the second 
scenario includes other alternatives. The first scenario alternatives were: Anti-
thymocyte globulin, a combination of Tacrolimus/Mycophenolate mofetil (MMF) 
and Cyclosporin/MMF for the induction, initial, and maintenance phase 
respectively. The second scenario were: Basiliximab, Cyclosporin/Everolimus and 
Cyclosporin/Mycophenolate Sodium (MPS). Hospital services, rejection treatment 
and diagnostic resources were the same for both scenarios. RESULTS: The costs 
for the different scenarios were lower in the second option than for the first case. 
In the first scenario the total cost per patient at all stages of kidney 
transplantation was US$40,210.28; with the second option was US$39,414.30; 
implying a cost saving of US$795.98 (2% less than the first option). 
CONCLUSIONS: From the perspective of the institution, it is important to review 
the treatment choices in order to achieve more efficiency in the resources use 
with the maximum effectiveness. The opportunity cost of the graft is high in the 
transplantation area.  
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OBJECTIVES: The main objective of the study is to compare and analyze the 
costs of various renal replacement interventions (dialysis, and renal 
transplantation). METHODS: A cross-sectional observational study was 
conducted at KIMS Hospital, Hyderabad, India for a period of six months. All the 
renal replacement therapy patients willingness to participate in the study was 
included. The data collected were cost of dialysis, renal transplantation, 
medications, consultation fee, transportation cost. We analyzed the average 
monthly and annual cost of Renal Replacement Therapies (RRT). RESULTS: A 
total of 100 patients were enrolled during the study period. Out of 100 patients, 
80 dialysis and 20 renal transplantation patients, majorities of them were in the 
age group of 41-60 year 66(66%) and men 63(63%) followed by women 37(37%). 
The cost for the dialysis for each time is Rs.1250. The average frequency of 
dialysis three times per week. The average monthly and annual cost of dialysis 
per patients was found to be Rs.15000 and Rs.1,80,000. The cost for the 
transplantation procedure was found to be Rs.1,40,000. The most commonly 
used Immunosuppressive agents were Tacrolimus, Mycophenolate Mofetil and 
Deflazacort. The average monthly costs of Immunosuppressive agents were 
Rs.8160-16000, Rs.2400-4800 and Rs.600-800 respectively. The average 
consultation fee for each time was found to be Rs.350. CONCLUSIONS: They are 
also several approaches to reduce the annual cost of renal replacement therapy 
(RRT). Obviously in long term, the most important factor is to reduce the number 
of patients with ESRD. This can be achieved by preventing the progression of 
renal disease. In India, the most frequent causes of ESRD are diabetes and 
hypertension. Early detection and treatment of these diseases play a vital role in 
the prevention of progression of renal failure and to postpone the need of RRT to 
an extent.  
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OBJECTIVES: To examine the economic burden and treatment patterns of 
chronic kidney disease (CKD) in the U.S. veteran population. METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
Patients diagnosed with CKD were identified using International Classification of 
Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis codes 585.xx, 
250.4xx, 791.0x, 583.xx, and 403.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure treatment 
patterns, costs and utilization distribution in the sample. Treatment patterns 
were examined 60 days after the identification date, and costs and utilization 
were examined for the 1-year follow-up period. RESULTS: The total number of 
U.S. veterans diagnosed with CKD in the VHA study population from 2005 to 2012 
was 433,771. The top treatments for CKD patients were simvastatin (n=159,532, 
36.78%), lisinopril (n=135,660, 31.27%), omeprazole (n=93,449, 21.54%) and 
furosemide (n=90,114, 20.77%). Other treatments included insulin, metoprolol 
tartrate, and amlodipine besylate, all of which showed less than 20% of patient 
use. The top two comorbidities for CKD patients were hypertension and diabetes. 
The percentage of patients with follow-up inpatient visits was 27.23%, which 
translated into $11,927 in inpatient visit costs per patient. The percentage of 
patients with follow-up outpatient visits was 99.56%, incurring $8614 in 
outpatient costs per patient. Patients with pharmacy visits (94.61%) incurred 
$1869 in pharmacy costs. The average number of CKD patients with blood urea 
nitrogen test results was 349,750 (80.63%), and the test result mean was 27.01. 
The average number of CKD patients with creatinine estimated Glomerular 
Filtration Rate (eGFR) test results was 243,774 (56.20%) and the result mean was 
50.67. CONCLUSIONS: Inpatient costs for CKD patients were responsible for more 
than half of the total costs. Laboratory test results should always be considered 
when interpreting drug effects.  
